Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Comparative study of adipose tissue derived mesenchymal stem cells with rapamycin on paraquat-induced acute lung injury and pulmonary fibrosis in a mouse model: histological and biochemical study.

Fikry H., Saleh LA., Sadek DR.

Animal Study on Chronic Inflammation, Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40665395
PMCID
PMC12265330
DOI
10.1186/s13287-025-04498-w
Citations
2

Abstract (original English)

Background The most noticeable consequence of paraquat (PQ) toxicity is pulmonary fibrosis. Mesenchymal stem cells have the remarkable ability to self-renew and differentiate into many cell types. One such type is adipose tissue-derived Mesenchymal Stem Cells (AT-MSCs), which are derived from adipose tissue. Thus, the purpose of this study was to compare the effects of AT-MSCs and rapamycin on paraquat-induced acute lung injury and pulmonary fibrosis in a mouse model. Methods Fifty female mice were randomly allocated to four groups. Group I (control group) received the drug solvent using the same route of administration for the same duration as the corresponding experimental groups. Group II (pulmonary fibrosis group) lung injury was induced by injection of PQ at a dosage of 40 mg/kg. Group III (AT-MSCs group) received 1.0 × 10 5 cells/mouse of male AT-MSCs. Group IV (rapamycin group) received 2.5 mg/kg/day diluted in 1% Dimethyl sulfoxide orally for two weeks. Lung tissue was harvested at the end of the experiment and analyzed by light and electron microscopy in addition to immunohistochemistry evaluation of p53. Samples were also taken to -80 for identification of the Y chromosome (SRY gene) and biochemical testing in the lung tissue. The injured lung was improved with AT-MSCs. Just like the control group, they restored p53 levels. Results Following injection with AT-MSCs, th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsParaquatAcute Lung InjuryMesenchymal Stem CellsMiceSirolimusMesenchymal Stem Cell TransplantationPulmonary FibrosisFemaleAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research